Benzodiazepine analogs

Abstract: Benzodiazepines of the general formula 1: are disclosed: R represents H, alkyl, alkenyl, cycloalkyl or cycloalkenyl each with up to 8 carbon atoms, phenylalkyl with an alkylene chain of 1 to 3 carbon atoms and optionally substituted on the phenyl radical with one or two substituents selected from the group consisting of Cl, Br, F, CN, CF₃, NO₂, lower alkyl, and OCH₃, or represents a phenyl radical which is optionally substituted with one or two substituents selected from the group consisting of Cl, F, Br, CN, I, CF₃ NO₂, lower alkyl and OCH₃, or represents a 5-membered or 6-membered heterocyclic radical with 1 or 2 heteroatoms from the group consisting of O, N and S; R₁ represents H or, together with R₂, forms a bond. R₂ and R₄ independently of one another represent H, or an alkyl radical with 1 to 6 carbon atoms, or represent a phenylalkyl radical with an alkyl chain of 1 to 3 carbon atoms and optionally substituted on the phenyl radical with one or two substituents selected from the group consisting of Cl, Br, F, CN, CF₃, NO₂, CH₃, C₂H₅ and OCH₃, or R₂ together with R₁, forms a bond. R₃ is (CH₂) n CH or (CH₂) n -CR₁₄=CR₁₄, where n is between 0 and 5 inclusive and R₁₄ = H or a bond R₅ and R₆ independently of one another represent H, Cl, F, Br, NO₂, CN, CF₃, lower alkyl, or OCH₃ . R₇ and R₉ are independently CH₂ or C=0 . R₈ is where p and q are independently between 0 and 4 and the sum of p and q is 4 or less. R₁₁ and R₁₂ are independently H or a lower alkyl of between 1 and 5 carbon atoms.

Description: This invention relates to benzodiazepines and to their therapeutic use. Benzodiazepines (BZDs) are important therapeutic agents which act on the central nervous system as anxiolytic, hypnotic, and anti-convulsant agents (Colotta et al., J. Med, Chem. 1988 31,1). They are also used as sedatives and muscle relaxants. One example is diazepam, the structure of which is shown in the Figure. The physiological effect of BZDs is dose dependent. For example, at low doses diazepam is anxiolytic and anti-convulsant, and at higher doses it acts as a sedative and muscle relaxant. BZDs interact with neuronal membrane proteins, termed BZD receptors, which may be located in GABA-ergic synapses and are classified as peripheral, neuronal, and central receptors. Referring to the Figure, examples of some compounds with affinity for these BZD receptors are shown. These compounds have diverse structures and give rise to different physiological effects. For example, the β-carbolines, ZK91296, ZK93426 and FG7142 are a partial agonist, antagonist, and partial inverse-agonist, respectively. As used herein, an agonist refers to a compound having a similar physiological activity to a BZD, which produces a maximal response in a tissue even when it occupies less than all of the BZD receptor sites. A partial agonist is a compound having low efficacy, and producing a physiological response less than the tissue maximum, even when it occupies all available BZD receptor sites. Other examples of partial agonists include CL218872 and CGS9896 (the Figure). An inverse-agonist is a compound which produces the opposite physiological effect of an agonist; a partial inverse-agonist has some of the properties of an inverse-agonist. Examples of inverse-agonists include β-carboline derivatives such as βCM, βCE and Ro 15-4513 (the Figure); an example of partial inverse agonist is 3-ethoxy-β-carboline. An antagonist is a compound which reduces or eliminates the physiological activity of an agonist or inverse-agonist on a tissue, and which has little intrinsic activity on the tissue by itself. Another example of an antagonist is RO 15-1788 (the Figure). Partial agonists may also have some antagonist-like properties. Dua et al. (J. Indian. Chem. Soc., 1986 63,425) demonstrated that introduction of hydroxy, alkoxy, and carboxy groups at the 3-position of 1, 4 benzodiazepines produces anxiolytic compounds, i.e., BZD agonists. Introduction of a morpholino group or methoxy benzoyloxy group at this position also produces compounds with appreciable anxiolytic activity, but devoid of CNS depression activity, indicative of their BZD antagonistic nature. Id. Swiss Patent No. CH-A-494765 discloses the preparation and activity of a number of 1,4 benzodiazepine derivatives, having an amino group at the 3-position. Boltze et al. US Patent 4,647,560, the disclosure of which is to be regarded as hereby incorporated by reference, describes BZDs, derived from 1,4 benzodiazepines, useful for treatment of cerebral disorders caused by old age, as well as disorders of learning and memory. These compounds have substitutions at the 3-position, including unsaturated ring structures. These compounds have no affinity for BZD receptors and show no anxiolytic activity, but exhibit potent phychotropic activity in animals. The invention provides BZDs of the general formula where: R represents H, alkyl, alkenyl, cycloalkyl, or cycloalkenyl, each with up to 8 carbon atoms; phenylalkyl with an alkylene chain of 1 to 3 carbon atoms and optionally substituted on the phenyl radical with one or two substitutents each independently selected from the group consisting of Cl, Br, F, CN, CF₃, NO₂, lower (C1-5) alkyl, and OCH₃, or represents a phenyl radical which is optionally substituted with one or two substituents each independently selected from the group consisting of Cl, F, Br, CN, I, CF₃, NO₂, lower (C1-5) alkyl, and OCH₃; R₁ represents H or, together with R₂, forms a bond; R₂ and R₄ each independently represents H, or an alkyl radical with 1 to 6 carbon atoms, or represent a phenylalkyl radical with an alkyl chain of 1 to 3 carbon atoms and optionally substituted on the phenyl radical with one or two substitutents each independently selected from the group consisting of Cl, Br, F, CN, CF₃, NO₂, lower (C1-5) alkyl, and OCH₃, or R₂ together with R₁ forms a bond; R₃ is (CH₂) n -CH=C, where n is between 0 and 5 inclusive; R₅ and R₆ each independently represents H, Cl, Br, F, CN, CF₃, NO₂, lower (C1-5) alkyl, or OCH₃; R₇ and R₉ are C=0; R₈ is where p and q are independently between 0 and 4 and the sum of p and q is 4 or less; and R₁₁ and R₁₂ are independently H or a lower (C1-5) alkyl (C1-5 means between 1 and 5 carbon atoms, inclusive). The compounds can also be provided in the form of pharmaceutically acceptable salts. Examples of suitable salts include those formed with hydrochloric, hydrobromic, sulphuric , maleic, acetic, or fumaric acid. In preferred embodiments, R is where R₁₃ is H or a halogen; R₁ is H; R₂ is H; R₄ is H or lower (C1-5) alkyl; and R₅ and R₆ are, independently, H or a halogen; R₃ is CH=C; R₈ is and R₁₁ and R₁₂ are both H. Particular preferred compounds include 3(RS)-1,3-dihydro-3-(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-ylidenemethyl)amino-1-methyl-5-phenyl-2H,1,4-benzodiazepin-2-one; 3(RS)-1,3-dihydro-3-(2,2 dimethyl-4,6-dioxo-1,3-dioxan-5-ylidenemethyl)amino-7-chloro-1-methyl-5-phenyl-2H,1,4-benzodiazepin-2-one; and 3(RS)-1,3-dihydro-3-(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-ylidenemethyl)amino-7-fluoro-1-methyl-5-phenyl-2H, 1,4-benzodiazepin-2-one. Where the compounds can occur in the form of optical antipodes, the compounds include the racemate and the individual enantiomers. The racemate can be split by the customary route by salt formation with an optically active acid and fractional crystallization of the diastereomeric salts, or by chromatography on an optically active carrier material. The BZDs of formula (1) differ from prior BZDs in their structure and pharmacological action. We have found compounds of formula (1) to have no significant affinity for the peripheral BZD receptor, but have potent binding affinity for the neuronal BZD receptor. The BZDs potentiate pentylenetetrazole (PTZ)-induced convulsion, indicating their reverse agonist character at the central BZD receptor. Furthermore, they antagonise pentobarbital sleeping time in rats, indicating that they possess antagonist or stimulant activity. We have found BZDs of formula (1) to facilitate learning and/or memory processes by reversing a negative modulatory influence of endogeneous diazepam-like ligands for BZD receptors. Thus, the BZDs are suitable for treatment of disorders in cerebral function caused by old age, such as the various forms of presenile and senile dementia of the Alzheimer type. They are also useful for treatment of alcohol and BZD dependence. Compositions for treating cerebral disorders include an amount effective therefore of a compound of the invention, in an admixture with a diluent, e.g. saline, or a unit dose of one of the compounds admixed with a carrier in the form of a tablet, capsule or ampule. The compositions can be used for treating a disorder in learning or memory; or alcohol or benzodiazepine dependence by administering to a patient in need thereof an amount effective therefore of one of the above compounds. Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof. The drawing is first briefly described. The figure is a group of structural representations of various known compounds having affinity for BZD receptors, as discussed above. Compounds of formula (1) can be synthesized generally as described by Boltze et al., supra . Below are examples of such syntheses. Those in the art will recognize that other examples of the claimed compounds can be synthesized according to the general methods of these examples. Generally, a 3-aminobenzodiapine of formula 2 (where each group is as defined above) is condensed with a compound of formula 3 (where each group is defined as above, and R₁₄ can be hydrogen, methyl or ethyl). A compound of formula 2 can be prepared from a 3-hydroxy compound using published methods (J. Het. Chem. 1967 4,647 J. Org. Chem. 1962 27,1695; and US Patent 3,198,789) or from a 1,3-dihydrobenzodiazepine-2-one (e.g., EP 167,919). A compound of formula 3 can be prepared from commercially available meldrum acid and trimethyl or triethylorthoformate, and some are commercially available (e.g. dimedone, 5,5-dimethyl-1,3-cyclohexanedione). Resolution of the resulting 3-aminobenzodiazepines can be achieved by published methods e.g., as described in J. Org. Chem. 1987 52,955. The condensation reactions are preferably carried out in an inert organic solvent, e.g., an alcohol, ethoxyethanol, dimethoxyethane, tetrahydrofuran, dimethylformide, dichloromethanol, or chloroform with the reaction temperature maintained at between 22°C and 100°C, most preferably, room temperature. The intermediates and final products are isolated and purified by standard methods, e.g., column chromatography or crystallization. Purity is determined using chromatographic, spectroscopic, and chemical analysis. Example 1: 1,3-dihydro-1-methyl-3-oximino-5phenyl-2H-1,4-benzodiazepine-2-one 20ml of tert-butylalcohol were added to a suspension of potassium tert-butoxide (2 to 5g) in 60ml dry tetrahydrofuran at -20°C under nitrogen. A solution of 1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one (2.5g) in 25ml of tetrahydrofuran was then added dropwise. The resulting dark amber colored solution was stirred for 2 hours at -20°C and treated with 1.74ml of isoamylnitrite. The dark red solution was then warmed to 0°C over 15 minutes and quenched with a solution of 6ml ice-cold water and 2ml acetic acid. The solvents were removed in vacuo and the residue partitioned between ethylacetate and brine. Organic extracts were dried using Na₂SO₄, and then concentrated. The resulting semi-solid compound was triturated with ether to give 2.23g of a yellow-tan colored product, having an R f = 0.12 in silica gel: chloroform/acetone = 9:1 (TLC). Example 2 : 3(RS)-amino-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one A solution of 2.0g of 1,3-dihydro-1-methyl-3-oximino-5-phenyl-2H-1,4-benzodiazepin-2-one in 60 ml of ethanol was treated with a slurry of Raney nickel (4g) in 20ml of ethanol. The resulting suspension was hydrogenated under 60 p.s.i. at 20-25°C. The catalyst was filtered off with a celite pad and the filtrate concentrated to provide 2.0g of product having an R f = 0.49 on TLC. Example 3 : 2,2-dimethyl-4,6-dioxo-5-methoxymethylene-1,3-dioxane 10g of meldrum acid were dissolved in 39ml of trimethylorthoformate and the mixture refluxed at 90°C under nitrogen atmosphere for 3 hours. After cooling at room temperature, pale yellow solid was collected by filtration, washed with a small amount of trimethylorthoformate, petroleum ether, then dried to yield 7.8g product. Example 4 : 3-(RS)-1,3-dihydro-3-(2,2-dimethyl-4,6-dioxo-1,3-dioxane-5-ylidenemethyl)amino-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one A solution of 3-(RS)-amino-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one (0.33g with slight impurities), and 2,2-dimethyl-4,6-dioxo-5-methoxymethylene-1, 3-dioxane (0.186g) in 10ml of ethanol was refluxed for 3 hours and cooled to 20-25°C. The resulting colorless solid was collected by filtration, washed with cold water, and dried to yield 0.28g product having an R f = 0.27 in TLC. Compounds of formula (1) can be made into pharmaceutical formulations which include non-toxic, inert, pharmaceutically suitable excipients. The formulations may be provided in the form of individual tablets, capsules, pills, suppositories and ampules, in which the content of active compound corresponds, e.g., to a fraction of an individual dose for a human patient. Such tablets can contain the active compound or compounds alongside the customary excipients, such as fillers, binders, humectants, disintegrating agents, solution retarders, absorption accelerators, wetting agents, adsorbents, and lubricants. The active compound or compounds, optionally together with one or more of the above-mentioned excipients, can also be in microencapsulated form. The active compounds or the pharmaceutical formulations can be administered orally, parenterally rectally, or intravenously. In general, it is advantageous to administer the active compound or compounds in amounts of about 0.01 to about 10, preferably 0.1 to 1mg/kg of body weight every 24 hours in the case of parenteral (intravenous or intramuscular) administration, and in amounts of about 0.05 to about 100, preferably 0.1 to 10 mg/kg of body weight every 24 hours in the case of oral administration, if appropriate in the form of several individual doses, in order to achieve the desired results. An individual dose preferably contains the active compound or compounds in amounts of about 0.01 to about 30, in particular 0.05 to 3mg/kg of body weight.

Claims: A benzodiazepine of the formula: where: R represents H, alkyl, alkenyl, cycloalkyl or cycloalkenyl, each with up to 8 carbon atoms; phenylalkyl with an alkylene chain of 1 to 3 carbon atoms and optionally substituted on the phenyl radical with one or two substituents each selected from the group consisting of Cl, Br, F, CN, CF₃, NO₂, lower (C1-5) alkyl, and OCH₃; or represents a phenyl radical which is optionally substituted with one or two substituents selected from the group consisting of Cl, F, Br, CN, I, CF₃, NO₂, lower (C1-5) alkyl, and OCH 3; R₁ represents H or, together with R₂, forms a bond; R₂ and R₄ independently of one another represent H or an alkyl radical with 1 to 6 carbon atoms, or represent a phenylalkyl radical with an alkyl chain of 1 to 3 carbon atoms and optionally substituted on the phenyl radical with one or two substituents each selected from the group consisting of Cl, Br, F, CN, CF₃, NO₂, lower (C1-5) alkyl, and OCH₃; R₂ together with R₁, forms a bond; R₅ and R₆ independently of one another represent H, Cl, Br, F, CN, CF₃, NO₂, lower (C1-5) alkyl, or OCH₃; R₃ is (CH₂) n CH=C, where n is between 0 and 5 inclusive; R₇ and R₉ are C=0; R₈ is p and q are independently between 0 and 4 and the sum of p and q is 4 or less; and R₁₁ and R₁₂ are independently H or a lower alkyl of between 1 and 5 carbon atoms; or a pharmaceutically acceptable salt of said benzodiazepine. A compound according to Claim 1, wherein R is where R₁₃ is H or a halogen; R₁ is H; R₂ is H; R₄ is H or lower alkyl; and R₅ and R₆ are independently H or a halogen. A compound according to Claim 1 or Claim 2, wherein R₃ is CH=C. A compound according to Claim 3, wherein R₈ is A compound according to Claim 4, wherein R₁₁ and R₁₂ are both H. A benzodiazepine selected from 3(RS)-1,3-dihydro-3-(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-ylidenemethyl)amino-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one; 3(RS)-1,3- dihydro-3-(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5- ylidenemethyl)amino-7-chloro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one; and 3(RS)-1,3-dihydro-3-(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-ylidenemethyl)amino-7-fluoro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one; or a pharmaceutically acceptable salt of any of the said benzodiazepines. A pharmaceutical composition for treating cerebral disorders comprising an amount effective therefor of a compound according to any preceding claim in admixture with a diluent or carrier. A unit dose of a composition according to Claim 7 in the form of a tablet, capsule or ampule. A compound according to any of Claims 1 to 6 for use in treating cerebral disorders, or disorders in learning or memory, or in the treatment of alcohol or benzodiazepine dependance. Use of a compound according to any of Claims 1 to 6 for the manufacture of a medicament for use in treating cerebral disorders, or disorders in learning or memory, or in the treatment of alcohol or benzodiazepine dependance.

Inventors: KIM SUN HYUK, TAYLOR JOHN E, KIM, SUN HYUK, TAYLOR, JOHN E.
Applicants: BIOMEASURE INC, BIOMEASURE INC.
Application year: 1990
Main classification: C07D243
IPC codes: C07D243, A61K31, A61P25, C07D403, C07D401, C07D413, C07D405